Minh Trinh
Retina Specialist · Auburn, WANPI 1164926028
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,087 of the $3,937 with a category attached, or 78.4%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.
Across 75 payments — averaging $52.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$842
- Regeneron Healthcare Solutions, Inc.$751
- Harrow Eye, LLC$717
- Apellis Pharmaceuticals, Inc.$402
- AbbVie$375
- Eyepoint US, Inc.$224
- plus $626 from 9 others
What the payments were for
- Consulting fees$50013%
- Speaking & faculty fees$3509%
- Food & beverage$3,08778%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 10 | $842 |
| Regeneron Healthcare Solutions, Inc. | 28 | $751 |
| Harrow Eye, LLC | 5 | $717 |
| Apellis Pharmaceuticals, Inc. | 5 | $402 |
| AbbVie | 10 | $375 |
| Eyepoint US, Inc. | 4 | $224 |
| Genentech USA, Inc. | 4 | $211 |
| Astellas Pharma US Inc | 2 | $132 |
| Dutch Ophthalmic, USA | 1 | $91 |
| Regeneron | 1 | $74 |
| Neurotech Pharmaceuticals, Inc. | 1 | $34 |
| Genentech, Inc. | 1 | $31 |
| Alcon | 1 | $24 |
| Bausch & Lomb Americas Inc. | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 49 | $2,092 |
| Ofloxacin | 31 | $382 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $104 |
| Latanoprost | 11 | $101 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Auburn
- Rahul MandigaAuburn$17K
- Benjamin ReissAuburn$2K
- George KoRenton$28K
- Evelyn FuPuyallup$22K
- Himanshu BandaTacoma$15K
- Peter ClarkWenatchee$7K
- Michael GilbertBellevue$3K
- David DruckerSeattle$1K
- Brenda Myers PowellFederal Way$422
- Kinza AhmadEverett$363
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.